NewAmsterdam Pharma Company NV - Warrants (15/11/2027) Total Liabilities

The latest total liabilities for NAMSW is $73M as of June 2026. That compares with $37M in the prior-year period — up 99.5% year over year. Investors often review this figure alongside NewAmsterdam Pharma Company NV - Warrants (15/11/2027)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, NAMSW's total liabilities moved from $37M to $73M — a 99.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in NewAmsterdam Pharma Company NV - Warrants (15/11/2027)'s operating scale or balance-sheet position.

A total liabilities figure of $73M for NAMSW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting NAMSW's total liabilities ($73M), review year-over-year change from $37M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.